ESMO 2023 [1]
11. Mayo 2023 0:00 - 13. Mayo 2023 0:00
Presentaciones
Efficacy and safety of first line ribociclib + letrozole in patients with de novo metastatic disease and late recurrence from (neo) adjuvant therapy in MONALEESA-2J O’Shaughnessy et al.
Descargar póster [2]
|
Correlation of circulating tumor DNA (ctDNA) or Thymidine Kinase activity (TKa) Dynamic Patterns with tumor response in patients (pts) with hormone receptor (HR)+ human epidermal growth factor 2 (HER2)– advanced breast cancer (ABC) on ribociclib (RIB) + letrozole (LET) in BioItaLEE trialG Arpino
Descargar póster [3]
|
Valora este contenido:
todavía no hay valoraciones